PARP-话题@MedSci

#PARP#

95篇内容 | 2772人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621357, encodeId=1f89162135ea9, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Cell Death Dis：PARP-1缺失可缓解糖尿病性动脉粥样硬化进展, objectType=article, longId=187770, objectId=5e0018e770ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e0018e770ee, replyNumber=0, likeNumber=73, createdTime=2020-02-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e0018e770ee, moduleTitle=Cell Death Dis：PARP-1缺失可缓解糖尿病性动脉粥样硬化进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e0018e770ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621356, encodeId=20f616213561f, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Clovis的Rubraca超越了多个PARP抑制剂竞争对手，在前列腺癌领域获得FDA的优先审查, objectType=article, longId=186457, objectId=94c818645e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94c818645e5b, replyNumber=0, likeNumber=98, createdTime=2020-01-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94c818645e5b, moduleTitle=Clovis的Rubraca超越了多个PARP抑制剂竞争对手，在前列腺癌领域获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94c818645e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621355, encodeId=d570162135530, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=28, createdTime=2020-01-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621354, encodeId=9f79162135437, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查, objectType=article, longId=186379, objectId=d24f1863e995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24f1863e995, replyNumber=0, likeNumber=72, createdTime=2020-01-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24f1863e995, moduleTitle=默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24f1863e995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621353, encodeId=ff7c16213538a, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=朱耀教授：2019年前列腺癌PARP抑制剂治疗的研究进展, objectType=article, longId=186164, objectId=e0021861645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0021861645c, replyNumber=0, likeNumber=66, createdTime=2020-01-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0021861645c, moduleTitle=朱耀教授：2019年前列腺癌PARP抑制剂治疗的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0021861645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621352, encodeId=c7f41621352f9, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗, objectType=article, longId=185523, objectId=1ffa1855237e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ffa1855237e, replyNumber=0, likeNumber=63, createdTime=2020-01-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ffa1855237e, moduleTitle=FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ffa1855237e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621351, encodeId=db9f1621351b1, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=NEJM：PARP抑制剂一线治疗卵巢癌3项临床试验, objectType=article, longId=185191, objectId=071118519167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=071118519167, replyNumber=0, likeNumber=90, createdTime=2019-12-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=071118519167, moduleTitle=NEJM：PARP抑制剂一线治疗卵巢癌3项临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=071118519167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621350, encodeId=21d01621350af, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, objectType=article, longId=184954, objectId=668a18495452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=668a18495452, replyNumber=0, likeNumber=71, createdTime=2019-12-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=668a18495452, moduleTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=668a18495452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621349, encodeId=ee11162134965, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=胡夕春教授：PARP抑制剂推进肿瘤精准诊疗, objectType=article, longId=184915, objectId=c84a184915b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a184915b0, replyNumber=0, likeNumber=68, createdTime=2019-12-20, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a184915b0, moduleTitle=胡夕春教授：PARP抑制剂推进肿瘤精准诊疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a184915b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621348, encodeId=e1c6162134862, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗, objectType=article, longId=184297, objectId=a8b018429e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b018429e5e, replyNumber=0, likeNumber=84, createdTime=2019-12-08, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b018429e5e, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b018429e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621347, encodeId=673a162134e94, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, objectType=article, longId=184163, objectId=972b1841632b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=972b1841632b, replyNumber=0, likeNumber=58, createdTime=2019-12-06, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=972b1841632b, moduleTitle=PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=972b1841632b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621346, encodeId=4920162134676, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, objectType=article, longId=184088, objectId=1ff918408873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff918408873, replyNumber=0, likeNumber=0, createdTime=2019-12-05, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff918408873, moduleTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff918408873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621345, encodeId=b3ce1621345de, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=不一样的组合疗法——免疫治疗联合PARP抑制剂在肺癌的探索前景, objectType=article, longId=183964, objectId=5734183964f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5734183964f5, replyNumber=0, likeNumber=74, createdTime=2019-12-04, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5734183964f5, moduleTitle=不一样的组合疗法——免疫治疗联合PARP抑制剂在肺癌的探索前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5734183964f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621344, encodeId=3d7d1621344fa, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Onxeo喜获美国专利，允许将DNA损伤响应抑制剂AsiDNA与所有PARP抑制剂联合用于癌症治疗, objectType=article, longId=182458, objectId=fe5d1824588f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe5d1824588f, replyNumber=0, likeNumber=67, createdTime=2019-11-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe5d1824588f, moduleTitle=Onxeo喜获美国专利，允许将DNA损伤响应抑制剂AsiDNA与所有PARP抑制剂联合用于癌症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe5d1824588f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621343, encodeId=d9381621343a6, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, objectType=article, longId=180570, objectId=29001805e099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29001805e099, replyNumber=0, likeNumber=64, createdTime=2019-10-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29001805e099, moduleTitle=2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29001805e099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621342, encodeId=ffee1621342ed, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=70, createdTime=2019-10-07, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621341, encodeId=3ece1621341b6, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=74, createdTime=2019-10-06, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621340, encodeId=f21c162134089, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=PARP抑制剂在卵巢癌全程管理中的作用不容忽视, objectType=article, longId=178557, objectId=7b4b1e85578d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4b1e85578d, replyNumber=0, likeNumber=67, createdTime=2019-09-03, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4b1e85578d, moduleTitle=PARP抑制剂在卵巢癌全程管理中的作用不容忽视, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b4b1e85578d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621339, encodeId=c5ad1621339c7, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=28, createdTime=2019-08-17, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621338, encodeId=8c22162133856, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=63, createdTime=2019-08-11, rootId=0, userName=lishiwen, userId=fd4d20248280, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PARP

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

Cell Death Dis：PARP-1缺失可缓解糖尿病性动脉粥样硬化进展

2020-02-11

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

Clovis的Rubraca超越了多个PARP抑制剂竞争对手，在前列腺癌领域获得FDA的优先审查

2020-01-19

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-01-19

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

默沙东的PARP抑制剂Lynparza治疗卵巢癌获美国优先审查

2020-01-18

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

朱耀教授：2019年前列腺癌PARP抑制剂治疗的研究进展

2020-01-14

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

FDA批准PARP抑制剂Lynparza用于胰腺癌的维持治疗

2020-01-02

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

NEJM：PARP抑制剂一线治疗卵巢癌3项临床试验

2019-12-26

zhaojie88 (审核中...)

前往app查看评论内容

#PARP#

阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗

2019-12-21

lishiwen (审核中...)

前往app查看评论内容

#PARP#

胡夕春教授：PARP抑制剂推进肿瘤精准诊疗

2019-12-20

lishiwen (审核中...)

前往app查看评论内容

#PARP#

阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗

2019-12-08

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP抑制剂Lynparza在BRCA突变的晚期前列腺癌男性中有效率达80%

2019-12-06

lishiwen (审核中...)

前往app查看评论内容

#PARP#

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

2019-12-05

lishiwen (审核中...)

前往app查看评论内容

#PARP#

不一样的组合疗法——免疫治疗联合PARP抑制剂在肺癌的探索前景

2019-12-04

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Onxeo喜获美国专利，允许将DNA损伤响应抑制剂AsiDNA与所有PARP抑制剂联合用于癌症治疗

2019-11-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

2019 ESMO：PARP抑制剂Zejula成功治疗晚期卵巢癌

2019-10-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

lishiwen (审核中...)

前往app查看评论内容

#PARP#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

lishiwen (审核中...)

前往app查看评论内容

#PARP#

PARP抑制剂在卵巢癌全程管理中的作用不容忽视

2019-09-03

lishiwen (审核中...)

前往app查看评论内容

#PARP#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-08-17

lishiwen (审核中...)

前往app查看评论内容

#PARP#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2019-08-11

科室
- - 订阅+
  - 更多科室
工具
服务